title: Concerns about pregabalin: further experience with its potential of causing addictive behaviors.
abstract: Pregabalin (PRG) is approved for the treatment of neuropathic pain, partial seizures, and generalized anxiety disorder in many countries. Supported by case reports and a few studies there is an ongoing debate on PRG's potential to cause addictive behaviors. Considering that PRG is currently under investigation for the treatment of benzodiazepine dependence and withdrawal as well as relapse prevention in alcohol dependence, assessment of PRG's abuse and dependence potential is indispensable. We report the case of a 38-year-old female patient with borderline personality disorder and past alcohol abuse who developed PRG abuse. The patient took up to 800 mg PRG per day, initially administered to treat unspecific anxiety, and experienced euphoric feelings after PRG intake. In the further course, she increased the daily PRG dosage and consulted other physicians to receive additional PRG prescriptions. During reduction of PRG, the patient developed a moderate withdrawal syndrome with vegetative symptoms. Because of the early detection of the developing PRG abuse (4 months after first application of PRG), the development of PRG dependence was prevented. This case illustrates the possibility of PRG to trigger the development of addictive behaviors and should encourage physicians to be very careful when administering PRG to patients with current or past substance-related disorders.
authors.affiliation: From the Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm University, Ulm, Germany. maximilian.gahr@uni-ulm.de
authors.forename: Maximilian
authors.initials: M
authors.lastname: Gahr
authors.forename: Beate
authors.initials: B
authors.lastname: Franke
authors.forename: Roland W
authors.initials: RW
authors.lastname: Freudenmann
authors.forename: Markus A
authors.initials: MA
authors.lastname: Kölle
authors.forename: Carlos
authors.initials: C
authors.lastname: Schönfeldt-Lecuona
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000150:complications / Q000523:psychology / Q000534:rehabilitation; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D016739:Behavior, Addictive / Q000139:chemically induced* / Q000150:complications / Q000523:psychology; D001883:Borderline Personality Disorder / Q000150:complications* / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069583:Pregabalin; D013375:Substance Withdrawal Syndrome / Q000150:complications* / Q000523:psychology; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid